 |
| NSAIDs provoke a specific portfolio of differentially expressed genes in healthy colon of HNPCC patients |
16 July 2006 - American Association for Cancer Research (AACR)
Taking celecoxib, a COX-2 inhibitor better known as Celebrex, has been found to alter a specific 'signature' set of genes in the colons of patients at high risk for a hereditary form of colon cancer, according to a new study reported here at the 96th Annual Meeting of the American Association for Cancer Research. |
|
|
| Combination of Lipitor and Celecoxib at lower doses is most effective at limiting colon cancer development |
15 July 2006 - American Association for Cancer Research (AACR)
Combinations of Lipitor and Celebrex (celecoxib) at lower doses proved more effective at limiting colon cancer than higher doses of the drugs when given alone, according to research reported at the 96th Annual Meeting of the American Association for Cancer Research here today. |
|
|
| New NSAID drug protects against intestinal tumors |
15 July 2006 - American Association for Cancer Research (AACR)
In mouse models of intestinal cancer, use of an anti-inflammatory drug eliminated all of the cancer-causing risks produced by a high-fat Western-style die, even when several genetic brakes to cancer formation were missing in the animals, say researchers from the Albert Einstein Cancer Center. |
|
|
| Biomarkers isolated from saliva successfully predict oral and breast cancer |
14 July 2006 - American Association for Cancer Research (AACR)
Screening for breast cancer and the early detection of other tumors one day may be as simple as spitting into a collection tube or cup, according to recent studies by UCLA researchers. In one early study based on a risk model, presented here at the 96th Annual Meeting of the American Association for Cancer Research, the UCLA scientists reported that genetic 'biomarkers' isolated in saliva predicted oral squamous cell carcinoma in about nine out of 10 cases. |
|
|
| New observational study suggests use of statins lowers risk of advanced prostate cancer |
14 July 2006 - American Association for Cancer Research (AACR)
Use of such cholesterol-lowering drugs as statins may reduce the risk of advanced prostate cancer, according to research that followed 34,428 U.S. men for more than a decade. The study, presented at the 96th Annual Meeting of the American Association for Cancer Research, found that men who used these medications had half the risk of advanced prostate cancer and a third of the risk of metastatic or fatal prostate cancer, compared to men who did not use cholesterol-lowering drugs. Risk of advanced prostate cancer fell with increasing duration of use of the drugs. The study did not find that use of cholesterol-lowering drugs had any influence on prostate cancer that is confined within the organ. |
|
|
| Antioxidant blood levels key to MnSOD gene associated prostate cancer risk |
13 July 2006 - American Association for Cancer Research (AACR)
Greater levels of selenium, vitamin E and the tomato nutrient lycopene have been shown to reduce prostate cancer in one out of every four Caucasian males, those who inherit a specific genetic variation that's particularly sensitive to oxidative stress. Conversely, if carriers of this genetic variant have low levels of these vitamins and minerals, their risk of aggressive prostate cancer increases substantially, as great as 10-fold, over their cohorts who maintain higher levels of these nutrients. |
|
|
| A new delivery system that transports gene silencing nanoparticles into tumor cells |
13 July 2006 - American Association for Cancer Research (AACR)
A novel delivery system that transports gene silencing nanoparticles into tumor cells has been shown to inhibit Ewing's sarcoma in an animal model of the disease. In this classic 'Trojan horse' approach, a protein called transferrin that normally delivers iron into cells is modified to also smuggle into tumor cells siRNA (short interfering RNA) encased in nano-sized sugar polymers. The siRNA was designed to target a specific growth-promoting gene called EWS-FLI1 that's active only in Ewing's sarcoma tumors. |
|
|
| Novel gene-silencing nanoparticles shown to inhibit Ewing's Sarcoma |
12 July 2006 - American Association for Cancer Research (AACR)
A novel delivery system that transports gene silencing nanoparticles into tumor cells has been shown to inhibit Ewing's sarcoma in an animal model of the disease.
In this classic 'Trojan horse' approach, a protein called transferrin that normally delivers iron into cells is modified to also smuggle into tumor cells siRNA (short interfering RNA) encased in nano-sized sugar polymers. The siRNA was designed to target a specific growth-promoting gene called EWS-FLI1 that's active only in Ewing's sarcoma tumors. |
|
|
| False positive screening for cancer found to be frequent and costly |
12 July 2006 - American Association for Cancer Research (AACR)
Cancer screening tests can frequently produce false positive outcomes that may result not only in anxiety but also additional economic costs as well, according to research conducted by scientists at the Henry Ford Health System, Detroit, Mich., and published in the December issue of Cancer Epidemiology, Biomarkers & Prevention. |
|
|
| Green tea Polyphenols Thwart Prostate Cancer development at multiple levels |
11 July 2006 - American Association for Cancer Research (AACR)
The polyphenols present in green tea help prevent the spread of prostate cancer by targeting molecular pathways that shut down the proliferation and spread of tumor cells, as well as inhibiting the growth of tumor nurturing blood vessels, according to research published in the December 1 issue of Cancer Research. |
|
|
| Green tea shown to prevent prostate cancer |
11 July 2006 - American Association for Cancer Research (AACR)
After a year's oral administration of green tea catechin, only one man in a group of 32 at high risk for prostate cancer developed the disease, compared to nine out of 30 in a control, according to a team of Italian researchers from the University of Parma and University of Modena and Reggio Emilia led by Saverio Bettuzzi, Ph.D. |
|
|
| Tumor-associated antigen may be candidate for cancer vaccines |
10 July 2006 - American Association for Cancer Research (AACR)
The pain and suffering of a broken bone may yield an unexpected benefit, a reduced risk of ovarian cancer. According to a new study reported in the May issue of Cancer Epidemiology, Biomarkers & Prevention, this unlikely pairing of unfortunate life events has a common thread: a protein called MUC1. What's more, this knowledge may offer new insights into a vaccine against ovarian cancer. |
|
|
| Researchers define celecoxib pathways and mechanisms for tumor reduction |
10 July 2006 - American Association for Cancer Research (AACR)
The anti-inflammatory drug Celebrex, or celecoxib, reduces tumor mass by encouraging cell death and discouraging both cell proliferation and the sprouting of new blood vessels that feed growing tumors, according to a study reported in the November issue of Molecular Cancer Research. |
|
|
| Nanoparticles, Nanoshells, Nanotubes: How tiny specks may provide powerful tools against cancer |
09 July 2006 - American Association for Cancer Research (AACR)
They're but a tiny speck, existing in a variety of forms: particles, tubes, shells, even a soccerball-like shape. They also share a common prefix: 'nano,' connoting their size, a billionth of a meter or roughly 25-millionth of an inch. Cancer researchers are exploring the potential of such nanostructures to exquisitely target cancer cells without harming surrounding tissue, and to image the formation of tumors long before they have a chance to become life-threatening. While diagnostics and approved therapies are years away, several are nearing clinical studies, while a few already are being tested in patients. |
|
|
| AACR launches Saving the Science initiatives to help displaced cancer researchers from the Gulf Region |
09 July 2006 - American Association for Cancer Research (AACR)
The American Association for Cancer Research extends its thoughts and heartfelt sympathies to all the citizens of New Orleans and other Gulf Coast communities as they rebuild their lives in the aftermath of Hurricane Katrina. In particular, the AACR wishes to assist its members and other cancer researchers in the region whose personal and professional lives have been devastated by this disaster. Valuable research that one day could save lives from cancer has been placed in jeopardy. |
|
|
| Updated data on novel HPV vaccine confirms efficacy in large population |
08 July 2006 - American Association for Cancer Research (AACR)
Updated data from a study on a promising new vaccine against a pre-cancerous cervical virus shows superior efficacy in preventing cervical pre-cancers and non-invasive cervical cancer, according to a study presented today during the American Association for Cancer Research's 4th Annual Frontiers in Cancer Prevention Research meeting in Baltimore. |
|
|
| Recycled or revamped therapeutics find novel anti-cancer applications |
08 July 2006 - American Association for Cancer Research (AACR)
A second look at compounds and drugs, some previously used to treat illness and conditions ranging from malaria to contraception, is giving new life to several abandoned therapies and new applications for existing drugs. From drugs such as the cottonseed extract gossypol, once tested as a male contraceptive in China, to arsenic, which can be made less toxic in an organic form, new applications are being investigated for effectiveness against solid tumors of various types. |
|
|
| Botox could help target resistant tumors for treatment |
08 July 2006 - American Association for Cancer Research (AACR)
The cosmetic treatment Botox may have a new use as an adjuvant to cancer therapy, providing an open door for chemotherapy and radiation treatments, according to a study published in the Feb. 15 issue of Clinical Cancer Research. |
|
|
| Innovative research set to push boundaries of cancer care |
07 July 2006 - American Association for Cancer Research (AACR)
Cancer researchers wielding opportunistic bacteria, vaccines, electric pulses, nano buckeyballs, and designer agents that enter the brain are being featured in a 'Novel Approaches' press conference at the Molecular Targets and Cancer Therapeutics International Conference. |
|
|
| Cells in mucus from lungs of high-risk patients can predict tumor development |
07 July 2006 - American Association for Cancer Research (AACR)
In a group of high-risk patients, a test that examined DNA from cells expelled in sputum for evidence of 'silenced' genes correctly identified the majority of patients who were later diagnosed with lung cancer, say researchers in a study published in the March 15 issue of Cancer Research. |
|
|
| High dietary calcium intake may increase prostate cancer risk |
07 July 2006 - American Association for Cancer Research (AACR)
Men with a high intake of dietary calcium are at greater risk of developing prostate cancer, according to a study presented today during the American Association for Cancer Research's 4th annual Frontiers in Cancer Prevention Research meeting in Baltimore. |
|
|
| How good fats, bad fats and other dietary patterns may influence risk for cancer |
06 July 2006 - American Association for Cancer Research (AACR)
Though scientists have long suspected that diet and obesity play a significant role in cancer risk, the latest results are suggesting the problem may be more serious than previously thought. Updated population studies suggest that the projected burden of cancer resulting from overweight and obesity may thwart other efforts to reduce cancer incidence over the next couple of decades, including curtailment of smoking. |
|
|
| Good fats, bad fats and other dietary patterns may influence risk for cancer |
06 July 2006 - American Association for Cancer Research (AACR)
Updated population studies suggest that the projected burden of cancer resulting from overweight and obesity may thwart other efforts to reduce cancer incidence over the next couple of decades, including curtailment of smoking. |
|
|
| Studies throw light on biomarkers which predict subsets of patients where Gefitinib has the greatest benefit |
06 July 2006 - American Association for Cancer Research (AACR)
The drug gefitinib (Iressa) was approved by the U.S. Food and Drug Administration in May 2003 under the agency's accelerated approval program for the treatment of patients with non-small cell lung cancer who had failed two or more courses of chemotherapy. Consistent with the requirements of accelerated approval, the sponsoring company continued to study the drug to verify the expected clinical benefit. In December 2004, the FDA released a statement notifying the failure of a large clinical trial of gefitinib to show an overall survival advantage compared to placebo in treating patients with lung cancer. In June 2005, FDA issued a new label for gefitinib 'that limits use to patients with cancer who in the opinion of their treating physician, are currently benefiting, or have previously benefited, from Iressa treatment.' |
|
|
| Pepper component hot enough to trigger suicide in prostate cancer cells |
06 July 2006 - American Association for Cancer Research (AACR)
Capsaicin, the stuff that turns up the heat in jalapeños, not only causes the tongue to burn, it also drives prostate cancer cells to kill themselves, according to studies published in the March 15 issue of Cancer Research. According to a team of researchers from the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, in collaboration with colleagues from UCLA, the pepper component caused human prostate cancer cells to undergo programmed cell death or apoptosis. |
|
|
| Targeted therapies showing great promise against colorectal cancer |
05 July 2006 - American Association for Cancer Research (AACR)
Results from a Phase III study of a new drug show promise for patients with colorectal cancer that has spread to other parts of the body, according to a study presented today during the 97th Annual Meeting of the American Association for Cancer Research. |
|
|
| Focus on lung cancer: How to prevent and treat it |
05 July 2006 - American Association for Cancer Research (AACR)
Since smoking became popular in America in the 1930s, lung cancer rates have continued to climb. Today, it is still the leading cause of cancer-related deaths, with totals more than the other five leading cancers combined. Armed with these sobering statistics, scientists have launched several innovative projects to find therapies that will effectively treat, and hopefully reduce the overall incidence of lung cancer. Several are being presented today during the American Association for Cancer Research's 4th annual Frontiers in Cancer Prevention Research meeting in Baltimore. |
|
|
| Broccoli Sprouts, Cabbage, Ginkgo Biloba and Garlic: A Grocery List for Cancer Prevention |
05 July 2006 - American Association for Cancer Research (AACR)
In the high-tech 21st century, the most rudimentary natural products continue to reveal exciting anti-cancer properties to scientists, offering people relatively simple ways to help protect themselves from the disease. |
|
|
| Alternative tobacco products: A better, safer option for smokers? |
04 July 2006 - American Association for Cancer Research (AACR)
According to the U.S. Centers for Disease Control and Prevention, nearly one-fourth of Americans are smokers. That's more than 60 million people who are at increased for lung cancer, the leading cause of cancer-related deaths nationwide. |
|
|
| Useful biomarkers to help prevent, diagnose and monitor treatment for cancer |
04 July 2006 - American Association for Cancer Research (AACR)
One of the goals for cancer prevention is to identify, as early as possible, molecular changes in the body that signal the onset of disease. Such 'biomarkers' may be isolated from subtle biological changes in an individual's cells, proteins or genetic makeup. Useful biomarkers to help prevent, diagnose and monitor treatment for cancer must share two essential characteristics: they must be consistently reliable, and they must display significant difference in expression between normal tissue and the various stages of cancer progression. |
|
|
| Researchers seek alternative for Leukemia patients resistant to standard therapies |
04 July 2006 - American Association for Cancer Research (AACR)
A study led by researchers from the Howard Hughes Medical Institute has found that dasatinib provides significant benefit in chronic myeloid leukemia patients resistant to Gleevec (imatinib), according to a study presented today during the 97th Annual Meeting of the American Association for Cancer Research. |
|
|
| New studies confirm celecoxib may help prevent colorectal cancer in high risk patients |
03 July 2006 - American Association for Cancer Research (AACR)
During the past year, the study of the potential use of cyclooxygenase-2 inhibitors to prevent colorectal and breast cancer has come under intense scrutiny. Recent research questioned the safety of these medicines as pain relievers, which was the initial indication, as well as for chemoprevention of cancer. Now, the latest data show that COX-2 inhibitors are highly effective in preventing pre-malignant tumors of the colon, and therefore may be useful in preventing colorectal cancer among high-risk patients. |
|
|
| Genetics, molecular biomarkers form molecular basis for cancer prevention risk-limiting strategies |
03 July 2006 - American Association for Cancer Research (AACR)
One of the goals for cancer prevention is to identify, as early as possible, molecular changes in the body that signal the onset of disease. Such 'biomarkers' may be isolated from subtle biological changes in an individual's cells, proteins or genetic makeup. |
|
|
| New strides being made in cancer chemoprevention |
03 July 2006 - American Association for Cancer Research (AACR)
Researchers have been trying to develop methods to identify why certain individuals are more susceptible to cancer and from these insights, determine the molecular causes of the disease. Based on these results, scientists are now seeking to pinpoint compounds that can reduce the incidence or recurrence of cancer, a field of study known as chemoprevention. Several studies presented today at the American Association for Cancer Research's 4th annual Frontiers in Cancer Prevention Research meeting in Baltimore are focusing on new directions in this promising new field. |
|
|
| Researchers try to develop methods to identify why certain individuals are more susceptible to cancer |
03 July 2006 - American Association for Cancer Research (AACR)
There are a number of things people are told to do to prevent cancer, eat well, exercise, don't smoke. However, despite these obvious preventive measures, many individuals will develop the disease. |
|
|
| New study shows thyroid drug reduces risk of colorectal cancer |
02 July 2006 - American Association for Cancer Research (AACR)
Long term use of L-thyroxin, the principal hormone secreted by the thyroid gland, reduces the risk of colorectal cancer by 50 percent, according to a study presented today at the American Association for Cancer Research's 4th annual Frontiers in Cancer Prevention Research meeting in Baltimore. |
|
|
| Molecular discoveries aim at advancing early diagnosis of cancers |
02 July 2006 - American Association for Cancer Research (AACR)
Molecular messages and signals circulating in blood or contained in cells lining the airway can identify early stage cancer, according to scientists presenting today at the 97th Annual Meeting of the American Association for Cancer Research in Washington, D.C. Researchers have discovered molecular signposts pointing to the presence of cancer, and those signs can provide physicians with early and, in some cases, more specific cancer detection opportunities. The goal of screening and early detection is to identify primary tumors at initial stages of development when they can be successfully controlled or cured with local therapy. |
|
|
| Research advances new cancer preventive strategies from myriad sources |
02 July 2006 - American Association for Cancer Research (AACR)
Promising new ways to prevent cancer emerge regularly from the laboratories of research institutions around the world. With every deposit to the scientific bank of knowledge about the human body and disease processes comes an opportunity to posit and test fresh theories. The results often suggest simple measures people can take to improve their chances of cheating cancer. |
|
|
| Inflammation and drugs to control this activity studies |
01 July 2006 - American Association for Cancer Research (AACR)
Inflammation cuts both ways. When invaded by an infectious agent, for example, the body calls on the forces of inflammation to fight and defeat the intruder. But when the biochemical processes of the immune system are either misdirected or chronically turned on, inflammation can lead to adversity, including some forms of cancer. For this reason, scientists are closely studying the link between inflammatory processes and tumor formation, while others are investigating anti-inflammatory drugs as a means to prevent and treat cancer, as seen by studies presented today at the 97th Annual Meeting of the American Association for Cancer Research. |
|
|
| Studies explore many complex linkages between smoking and cancer |
30 June 2006 - American Association for Cancer Research (AACR)
Researchers are delving deeper into the links between smoking and cancer, teasing out the genes and molecules involved as well as other factors that affect cancer risk. They have found, for example, a specific protein that decreases with smoking cessation. Genetic factors are also being implicated in the lung cancers of people who have never smoked. New studies are revealing an association between smoking and ovarian cancer, as well as between second-hand smoke exposure and lung cancer survival. |
|
|
| Vitamin D and Flavonoids examined for impact on breast and ovarian cancers |
29 June 2006 - American Association for Cancer Research (AACR)
While risk factors for breast and ovarian cancers include menopause, obesity, family history and specific genetic mutations, researchers also are looking at the role of diet in the development, as well as the treatment and prevention of these tumors. At the 97th Annual Meeting of the American Association for Cancer Research, two groups of scientists using sophisticated statistical techniques report their findings of possible preventive properties of Vitamin D against breast cancer. |
|
|
| Cancerous vs. healthy cells: Researchers identify the road to success |
28 June 2006 - American Association for Cancer Research (AACR)
Conventional cancer treatments are generally effective in wiping out tumor cells, but in the process they also may kill healthy cells. Researchers are focusing their efforts now on treatments that can target just the cancerous cells, without harming healthy tissue in their midst. These new types of drugs are known as targeted therapies, and physicians are studying their effectiveness and possible side effects in a variety of different types of cancer. Several targeted therapies are being studied alone and in combination to treat a variety of cancer types. In particular, cancerous brain tumors can be more difficult to treat than other cancers, and oncologists are developing therapies that target these cells to improve patients' survival. |
|
|
| Markers of gene, protein, or micro-RNA activity predict outcome in prostate and colorectal cancers |
27 June 2006 - American Association for Cancer Research (AACR)
Cancer researchers are working toward a future in which each patient's tumor will act like a crystal ball, revealing how oncologists should treat the cancer to obtain the best outcome. Currently, physicians cannot predict which patients with prostate cancer should receive extra therapy after surgery; or whether some of these patients have an indolent disease that does not even require surgery. Most patients with colorectal cancer have surgery, but some, even at the earliest stages, could benefit from additional treatment, if physicians only knew who. |
|
|
| Inflammation markers identify fatigue in breast cancer survivors |
26 June 2006 - American Association for Cancer Research (AACR)
Researchers at the University of California, Los Angeles have defined conditions associated with disabling fatigue that persists for years in almost a third of breast cancer survivors, according to a study in the May 1 issue of Clinical Cancer Research. |
|
|
| Scientists find environmental exposure to polychlorinated biphenyls being associated with non-Hodgkin lymphoma |
09 June 2006 - American Association for Cancer Research (AACR)
Scientists have found some additional evidence that environmental exposure to polychlorinated biphenyls may be associated with non-Hodgkin lymphoma, according to a study published in the December 1 issue of Cancer Research. By comparing blood levels of PCBs in 100 pairs of healthy volunteers and non-Hodgkin lymphoma patients, Anneclaire De Roos, Ph.D., assistant professor of epidemiology, Fred Hutchinson Cancer Research Center, and colleagues determined that high levels of three specific molecular forms of PCBs are linked to an increased risk of developing cancer that starts in patients' lymph tissue. |
|
|
| New study of the potential use of cyclooxygenase-2 inhibitors to prevent colorectal and breast cancer |
05 June 2006 - American Association for Cancer Research (AACR)
According to two studies presented today at the 97th Annual Meeting of the American Association for Cancer Research, the over-expression of the COX-2 enzyme is related to the growth and spread of colorectal tumors. COX-2 inhibitors may reduce the occurrence of the precursor, colorectal adenomas (benign tumors) in patients with a family history of the disease, as well as the development of sporadic colorectal tumors. |
|
|
| New study that that dasatinib provides significant benefit in chronic myeloid leukemia patients |
31 March 2006 - American Association for Cancer Research (AACR)
Imatinib, which blocks the irregular protein that allows the overproduction of abnormal white blood cells, has become a standard therapy for CML patients not undergoing stem cell transplantation. However, a number of patients have developed resistance to this treatment because their cancer cells are able to mutate and adapt. |
|
|
| The cosmetic treatment Botox may have a new use as an adjuvant to cancer therapy |
28 March 2006 - American Association for Cancer Research (AACR)
A study in mice, led by Bernard Gallez, Ph.D., professor of pharmacy at the Université de Louvain in Brussels, Belgium, found that by injecting Botulinum neurotoxin type A into two types of mouse tumors, the tumors' cellular vasculature opened, allowing for more effective destruction of previously resistant cancer cells. The study is the first to test the idea of using Botox against cancer and explores the possibility of its use as an adjuvant, assisting the effective delivery of chemotherapies and radiation. |
|
|
| Iressa holds promise and continue investigating its potential |
03 February 2006 - American Association for Cancer Research (AACR)
Oncologists believe that Iressa still holds promise and continue investigating its potential. Several studies presented at the Annual International Conference on Molecular Targets and Cancer Therapeutics coordinated by the American Association for Cancer Research, the National Cancer Institute and the European Organisation for Research and Treatment of Cancer explore the ways in which gefitinib may work on tumors and which patients may benefit the most. |
|
|
| Researchers trying to develop methods to identify why certain individuals are more susceptible to cancer |
12 December 2005 - American Association for Cancer Research (AACR)
Researchers have been trying to develop methods to identify why certain individuals are more susceptible to cancer and from these insights, determine the molecular causes of the disease. Based on these results, scientists are now seeking to pinpoint compounds that can reduce the incidence or recurrence of cancer, a field of study known as chemoprevention. Several studies presented today at the American Association for Cancer Research's 4th annual Frontiers in Cancer Prevention Research meeting in Baltimore are focusing on new directions in this promising new field. |
|
|
| Molecular biomarkers form molecular basis for cancer prevention risk-limiting strategies |
31 October 2005 - American Association for Cancer Research (AACR)
Useful biomarkers to help prevent, diagnose and monitor treatment for cancer must share two essential characteristics: they must be consistently reliable, and they must display significant difference in expression between normal tissue and the various stages of cancer progression. |
|
|
| Use of L-thyroxin reduces the risk of colorectal cancer |
28 October 2005 - American Association for Cancer Research (AACR)
Use of L-thyroxin, which is commonly used to treat hypothyroidism, for five or more years was associated with a significantly reduced risk of colorectal cancer
across study participants of all genders, ages, origins and religions, but reached statistical significance in Jewish females, participants aged 65 and older, and European-American born participants, which were the largest study sub-populations. |
|
|
| Health officials and doctors are trying to find less harmful alternatives to cigarette smoking |
30 July 2005 - American Association for Cancer Research (AACR)
Despite the risks, many people have trouble kicking this addictive habit of smoking. As a result, health officials and doctors are trying to find less harmful alternatives to cigarette smoking. But some products, like smokeless tobacco, may not be effective replacements, according to research presented today during the American Association for Cancer Research's 4th annual Frontiers in Cancer Prevention Research meeting in Baltimore. |
|
|
| New data on novel HPV vaccine confirms efficacy in large population |
08 July 2005 - American Association for Cancer Research (AACR)
Final results of the phase III study, originally published in early October, confirmed the vaccine's efficacy from available combined phase II and phase III data sets, incorporating an additional 7,000 patient records as compared to the interim results. The researchers concluded from these analyses that the administration of this vaccine, known as GARDASIL, is highly effective in preventing high-grade pre-cancerous illnesses and non-invasive cervical cancers. |
|
|
| Natural products continue to reveal exciting anti-cancer properties |
05 July 2005 - American Association for Cancer Research (AACR)
Five studies presented during the American Association for Cancer Research's 4th annual Frontiers in Cancer Prevention Research meeting in Baltimore, Md., add to the arsenal of research that shows adding certain vegetables and herbs to the diet can prevent or, in some cases, halt the growth of cancer. |
|
|
| Men with a high intake of dietary calcium are at greater risk of developing prostate cancer |
07 January 2005 - American Association for Cancer Research (AACR)
Researchers from the Division of Cancer Epidemiology and Genetics of the National Cancer Institute reviewed data from the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study to evaluate the relation between calcium, vitamin D, phosphorus as well as dairy products and occurrence of prostate cancer. The current research was based on 17 years of follow-up and 1269 incident cases of prostate cancer. |
|
|
| Component of plastic stimulates growth of certain prostate cancer cells |
03 January 2005 - American Association for Cancer Research (AACR)
An oestrogen-like chemical commonly used to synthesize plastic food containers has been shown to encourage the growth of a specific category of prostate cancer cell, potentially affecting the treatment efficacy for a subset of prostate cancers. |
|
|
| Stony Brook University medical researcher developing new medication to prevent colon cancer |
19 October 2004 - American Association for Cancer Research (AACR)
A Stony Brook University researcher is testing a new form of aspirin, one that is much more potent than its commercially available counterpart, but with almost none of the side effects, to determine whether it can be used to prevent colon cancer in patients who are prone to the disease. |
|
|
| Bloodroot alkaloid aids in exterminating sun-damaged skin cells in culture |
19 October 2004 - American Association for Cancer Research (AACR)
A common antibacterial and antifungal ingredient used in mouthwashes and tooth paste may have another positive medicinal use: protection against skin cancer. According to new studies, sanguinarine was shown to enhance production of proteins that induce cell death, or apoptosis, in cells damaged by ultraviolet-B radiation. The alkaloid also restricts skin cell production of other pro-proliferation proteins. |
|
|
| Hormone therapy's effect on breast density is not the same for all women, Group Health study finds |
18 October 2004 - American Association for Cancer Research (AACR)
Fred Hutchinson Cancer Research Center's Public Health Sciences Division houses the Clinical Coordinating Center for the Women's Health Initiative, or WHI, one of the largest National Institutes of Health-funded studies ever conducted in women. This 15-year, multimillion-dollar study, established in 1991, involves more than 160,000 women nationwide, including some 3,500 in Washington. |
|
|
| New gout drug shown to reduce risk from colorectal cancer |
18 October 2004 - American Association for Cancer Research (AACR)
A commonly prescribed drug used to treat gout may also offer some protection against colorectal cancer, according to a new study reported during the American Association for Cancer Research Third Annual International Conference on Frontiers in Cancer Prevention Research here. |
|
|
| High fiber intake reduces estrogen levels in Latina women |
18 October 2004 - American Association for Cancer Research (AACR)
Researchers from the Keck School of Medicine of the University of Southern California in Los Angeles, the University of Hawaii in Honolulu, and the University of Helsinki in Finland have shown that, in Mexican American women, higher intake of dietary fiber is associated with lower circulating estrogen levels. Because high estrogen levels have been linked to breast cancer, this finding could provide a significant step toward preventing breast cancer. |
|
|
| High fiber intake reduces estrogen levels in Latina women |
18 October 2004 - American Association for Cancer Research (AACR)
Researchers from the Keck School of Medicine of the University of Southern California in Los Angeles, the University of Hawaii in Honolulu, and the University of Helsinki in Finland have shown that, in Mexican American women, higher intake of dietary fiber is associated with lower circulating estrogen levels. Because high estrogen levels have been linked to breast cancer, this finding could provide a significant step toward preventing breast cancer. |
|
|
| New study in male smokers continues to provide clues into causes & prevention of multilple cancers |
17 October 2004 - American Association for Cancer Research (AACR)
The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study was initiated to test the effect of vitamin supplementation on the prevention of lung and other cancers. The trial ended in 1993, but ongoing follow-up of the participants continues, offering new insights into the causes and prevention of multiple diseases, including cancer. |
|
|
| New study confirms link between head and neck cancer and common Asian nut |
17 October 2004 - American Association for Cancer Research (AACR)
Disease Prevalence in Taiwan Corresponds to Increased Production of Betel Quid, a Nut Common to Asia and Infamous for Its Intoxicating Effects upon Chewing
SEATTLE, Over the past couple of decades, scientists have been perplexed by a substantial rise in the incidence of head and neck cancers among Taiwanese men. According to cancer statistics, the disease increased by 85 percent among men there from 1981 to 2000. |
|
|
| US researchers show cottonseed drug is cancer treatment booster Patient trials |
01 October 2004 - American Association for Cancer Research (AACR)
Geneva, Switzerland: New research from the United States has opened up the prospect that gossypol, a drug refined from cottonseed oil and previously tried and abandoned as a male contraceptive, could boost the effectiveness of treatment for prostate tumours and possibly other common cancers as well. |
|
|
| International study findings link acne-like rash to effectiveness of new targeted cancer treatment |
30 September 2004 - American Association for Cancer Research (AACR)
Acne is not a condition that anyone would welcome under normal circumstances, but an international study of a new targeted cancer treatment, cetuximab, has shown that patients who developed an acne-like rash responded better to the treatment than those who did not. |
|
|
| Trial shows which brain cancer patients benefit from temozolomide |
29 September 2004 - American Association for Cancer Research (AACR)
An international team of scientists and cancer specialists has identified which
patients with the deadly form of brain tumours called glioblastomas are likely to live longer if they are treated with temozolomide, and which patients are likely to get only marginal, if any, benefit. |
|
|
| New study results indicate arsenic could be suitable as first-line treatment in rare type of leukaemia |
29 September 2004 - American Association for Cancer Research (AACR)
Arsenic trioxide, a highly poisonous substance best known as an effective weed killer or pesticide and notorious for being a favourite 'weapon' of choice in murder mystery novels, is being re-invented as a treatment for a rare type of leukaemia. |
|
|
| New study links high carbohydrate diet to increased breast cancer risk |
06 August 2004 - American Association for Cancer Research (AACR)
Carb-conscious dieters may be lowering their risk of breast cancer while they're shedding pounds, based on the findings of research published in this month's edition of the journal Cancer Epidemiology, Biomarkers & Prevention. |
|
|
| ALL survivors bear genetic damage from life-saving chemotherapy |
07 July 2004 - American Association for Cancer Research (AACR)
Children who undergo chemotherapy and survive acute lymphocytic leukemia endure a 200-fold increase in the frequency of somatic mutations in their DNA, researchers from the University of Vermont Medical School reported in the July 1 issue of the journal Cancer Research. |
|
|
| Study links diabetes and colorectal cancer |
04 June 2004 - American Association for Cancer Research (AACR)
Diabetics are three times more likely to develop colorectal cancer than people with normal blood sugar levels, according to a team of scientists at the University of Cambridge, U.K., reporting in this month's edition of the journal Cancer Epidemiology, Biomarkers and Prevention. |
|
|
| RNAi delivery system crosses blood-brain barrier to target brain cancer |
01 June 2004 - American Association for Cancer Research (AACR)
Researchers have combined novel molecular targeting technologies to deliver gene-silencing therapy specifically to tumor cells shielded by a normally impermeable obstacle, the blood brain barrier. |
|
|
| Existing therapies applied to new use in broader spectrum of cancer care |
30 March 2004 - American Association for Cancer Research (AACR)
Researchers find new purpose for existing drugs to suppress colon cancer metastasis, secure post-radiation brain function, and trick tumors to gorge on a Trojan Horse vitamin. Drugs approved for treatment of specific maladies sometimes show unexpected benefits. Researchers at the 95th annual meeting of the American Association for Cancer Research highlighted how some drugs may one day offer previously unforeseen benefits for patients. |
|
|
| First treatment leading to a complete cure for childhood Leukemia |
28 March 2004 - American Association for Cancer Research (AACR)
Emil Frei III, M.D., who revolutionized chemotherapy and advanced the treatment of cancer worldwide, has received the inaugural American Association for Cancer Research Award for Lifetime Achievement in Cancer Research. |
|
|
| Three molecular-targeted compounds show promise against cancers in early clinical studies |
20 November 2003 - American Association for Cancer Research (AACR)
Early clinical studies show that a new generation of drugs that target signaling pathways, the internal channels through which cancer cell growth is controlled, and the body's own production of tumor-suppressing proteins hold promise for the treatment of a variety of tumors. Patient trials evaluated drug tolerance and potential anti-tumor activity against a variety of cancers such as renal cell, colorectal and non-Hodgkin's lymphoma of three compounds. |
|
|
| Scientists discover potential approaches to enhance existing cancer therapies |
19 November 2003 - American Association for Cancer Research (AACR)
Scientists today reported exciting discoveries to optimize existing cancer treatments. One set of studies demonstrated that the cell-killing effects of either radiation or standard chemotherapy drugs were enhanced when tumor cells such as melanoma were grown in dishes containing PABA, an ingredient in some sunscreens. |
|
|
| Proteins help identify patients who will respond better to different treatments in certain cancers |
19 November 2003 - American Association for Cancer Research (AACR)
Scientists today presented studies of proteomic and genomic markers that could help oncologists devise better treatment approaches for specific patients, and may improve clinical outcomes. The studies were presented here today at the International Conference on Molecular Targets and Cancer Therapeutics organized by the American Association for Cancer Research, National Cancer Institute and European Organisation for Research and Treatment of Cancer. |
|
|
| New drug target & biomarker for advanced childhood cancer discovered |
19 November 2003 - American Association for Cancer Research (AACR)
Scientists announced today that they have discovered a protein produced by advanced childhood cancers that provide s a new target for treatments and a new marker for the disease. Separately, researchers reported data on the crystal structures of two kinase proteins implicated in multiple cancers. The data on structure provides valuable information for the design of cancer therapeutics targeted at these proteins. |
|
|
| Circadian clock genes may provide targets for new cancer drugs |
18 November 2003 - American Association for Cancer Research (AACR)
A tumor's growth may be controlled by a complex, gene-controlled 'clock, and jamming that 'clock' can offer a new way to fight cancer, according to two studies presented today at the International Conference on Molecular Targets and Cancer Therapeutics organized by the American Association of Cancer Research, National Cancer Institute and European Organisation for Research and Treatment of Cancer in Boston. |
|
|
| New research finds tumor preventive qualities, damage reversal, in green tea |
28 October 2003 - American Association for Cancer Research (AACR)
Drinking green tea may do more than just thwart a head cold, according to research presented today at the American Association for Cancer Research Second Annual International Conference on Frontiers in Cancer Prevention Research. Green tea already is believed to help lower cholesterol and prevent heart disease, fight bacteria and dental cavities, and possibly aid weight loss. New studies are now suggesting the various potential anti-cancer benefits of the age-old beverage. |
|
|
| New studies show preventive value of food supplements |
28 October 2003 - American Association for Cancer Research (AACR)
Common spices and herbs contain ingredients that may prevent the formation of major tumors, such as intestinal and prostate cancers, according to research presented today at the American Association for Cancer Research's Second Annual International Conference on Frontiers in Cancer Prevention Research. In particular, recent studies are showing notable cancer prevention potential for the use of ginger extract and a traditional Chinese medicinal herb. |
|
|
| New clinical data indicate significant efficacy from scientifically designed treatments |
14 July 2003 - American Association for Cancer Research (AACR)
Two new therapies for metastatic cancer are showing significant clinical activity, according to research presented today at the 94th Annual Meeting of the American Association for Cancer Research. The studies examined the potential anti-tumor benefits of a combination therapy for colorectal cancer and a multi-targeted oral therapy for imatinib-resistant gastrointestinal stromal tumors. |
|
|
| New studies show combined therapies, new targets effective in fighting disease |
12 July 2003 - American Association for Cancer Research (AACR)
Armed with information about the function and capabilities of currently approved cancer therapies, researchers are beginning to develop more potent and successful treatments, according to research presented today at the 94th Annual Meeting of the American Association for Cancer Research. |
|
|
| Researchers identify new gene associated with breast cancer |
08 April 2003 - American Association for Cancer Research (AACR)
Researchers have identified a new gene, C35, that appears to be closely associated with breast cancer. Of the breast cancer tissues tested, more than sixty percent over-expressed the C35 gene, according to data published in the Proceedings for the 94th Annual Meeting of the American Association for Cancer Research. The study also found that the C35 gene was only over-expressed in breast cancer cells, and is not evident in any normal tissues in women. |
|
|
| Over-the-counter pain relievers effective in protecting against breast cancer |
08 April 2003 - American Association for Cancer Research (AACR)
Regular use of ibuprofen and aspirin inhibits the formation and growth of breast cancer, according to data published in the Proceedings for the 94th Annual Meeting of the American Association for Cancer Research. The data, taken from the National Cancer Institute's Women's Health Initiative Observational Study, concluded that weekly doses of non-steroidal anti-inflammatory drugs had a significant effect in reducing the risk of breast cancer. |
|
